Recently, increases in blood pressure (BP) and concomitant bradycardia, suggestive of autonomic dysre¯exia (AD), have been documented during functional electrical stimulation (FES) in individuals with a high spinal cord injury (SCI). If uncontrolled, this response could preclude the safe use of FES among such individuals. FES induced pain is partly related to stimulation of skin nociceptors. Therefore, measures to reduce skin sensitivity may reduce the risk of AD during FES. The purpose of this study was to determine if topical anaesthetic applied over the site of electrical stimulation could minimize the AD cardiovascular and hormonal responses to FES in individuals with SCI above the T6 level.
Introduction
In the early 1970s, the use of electrical current to stimulate paralysed musculature, a technique known as Functional Electrical Neuromuscular Stimulation (FES), was identi®ed as a treatment modality that could have signi®cant bene®ts for spinal cord injured (SCI) patients. 1, 2 Since then, FES has proven to be an eective means of eliciting functional movement in paralysed limbs and has the potential to reverse or alleviate many of the health problems associated with paralysis due to SCI. 3 Uses of FES in individuals with SCI may generally be categorized into three areas: rehabilitation, prevention and exercise (for a recent comprehensive review, see 4 ). To date, most reports regarding the use of FES in rehabilitation, prevention and exercise settings have been positive. However, recent evidence suggests that FES assisted training or therapeutic interventions may induce autonomic dysre¯exia (AD) in high level SCI patients. 5 AD occurs when a nociceptive stimulus distal to the level of the SCI triggers a mass sympathetic discharge, resulting in hypertension, piloerection, sweating and anxiety. This response has Correspondence: Dr Garry Wheeler, Ph.D.
Spinal Cord (1997) 35, 647 ± 651 been shown to be largely norepinephrine mediated. 6 A reactive parasympathetic component manifest by bradycardia, facial vasodilatation and vascular headache is also characteristic of the syndrome. Uncontrolled AD can result in serious health complications such as seizures, blindness or death, 7 which would pose an unacceptable risk to FES. Prior to Ashley et al 5 reporting the association between FES and AD, the risk for FES-associated AD 8 and exercise-induced hypertension 9 were dismissed as infrequent and relatively unimportant. In contrast, it has been the experience in our laboratory that, when monitoring heart rate (HR) and blood pressure (BP) continuously during FES with SCI patients, an AD response to FES is commonplace. Any method to reduce the magnitude of the blood pressure change with FES, or the intensity of the FES nociception perceived in sensory incomplete SCI patients, would make FES training safer and more widely applicable.
During FES, electrical current is passed from the surface electrodes through the skin into the muscle. This current causes the underlying motor nerves to discharge, thereby causing the muscles to contract. Theoretically, FES nociception could come from stimulation of one or a combination of the following: electrical activation of pain ®bres (A delta and C ®bres) of the skin, or muscle; isometric muscle contraction and its resultant ischemia, metabolites and/or musculotendinous stress. Currently, researchers examining the use of electrical muscle stimulation in able-bodied populations have attempted to produce a relatively low pain, yet eective contraction-inducing electrical stimulus. 10, 11 Another approach would be to reduce the pain sensitivity of the skin. The use of topical skin anaesthetic cream prior to invasive skin procedures such as venipuncture, arterial puncture or skin surgical procedures, has recently gained popularity. 12 A published report described one such cream (EMLA, a mixture of lignocaine and prilocaine -Astra Pharma Inc.) being applied to the skin of quadriplegics' legs in an attempt to reduce`re¯ex muscle spasm induced by the stimulus' thereby allowing more accurate FES-induced measurements of muscle contractile properties. 13 If this type of local anaesthetic cream could eectively reduce the FES induced skin nociception, suppression of the AD response may result. However, the overall advantage of this type of local anaesthetic cream would be diminished if the strength of the FES induced muscle contraction was reduced.
The purpose of this study therefore, was to determine if local anaesthetic cream at the site of FES application would: (a) reduce the AD-related cardiovascular response; (b) reduce the magnitude of the sympathetic output; and (c) aect the strength of the FES-induced quadriceps contraction.
Methodology
Prior to participation, all subjects were screened for contraindications to lower extremity FES, were informed of the nature and protocol of the study, and signed an informed consent. Seven subjects (six males, one female) with complete motor and sensory tetraplegia participated. Subject characteristics are summarized in Table 1 . Each testing session lasted approximately 2.5 h. Subjects arrived at the testing area 30 min prior to testing, having avoided any strenuous activity, caeine intake for at least 12 h, and having recently emptied their bladder. Prior to testing each subject was familiarized with the testing equipment and procedures, and the Rick Hansen Centre emergency medical protocol was followed in the event of uncontrolled AD. 14 
Experimental design
A two factor (cream type6stimulus intensity) repeated measures design was utilized. Subjects were tested on two separate sessions ± once using anaesthetic (EMLA) cream, and once using placebo cream. At each session, each leg was tested separately and was considered a quasi-independent limb in the analysis. The application of EMLA cream or placebo was double-blinded, and the order of application was randomly determined for each subject by the pharmacist, and the codes for the creams were broken at the conclusion of the investigation. The anaesthetic and placebo were in identical cream form. Five grams of cream were applied under occlusion to the skin overlying the quadriceps muscle. The cream covered an area of the skin corresponding to the size of the FES electrode, and provided analgesia to a depth of 3 mm.
12 After 1 h of application time, the occlusive dressing was removed, the topical cream wiped o, and the area cleansed with an alcohol swab in preparation for FES. For consistency between the test days, the location of the cream application and electrode placement was standardized by measurement of a set distance from the proximal pole of the patella for each subject. The muscle stimulator consisted of a four-channel neuromuscular stimulation device (Quadstim, Biomech Industries Edmonton Ltd.), which was connected to the subject via commercially available, reusable (1.5''63.5'') surface electrodes (Chattanooga Corp., TN). The proximal electrode was positioned over the motor point and the distal electrode over the musculotendinous junction of the quadriceps muscle to elicit knee extension. Stimulation parameters included square monophasic waves of 250 msec pulse width, 30 Hz frequency, 0 to 160 mAmps stimulus intensity, at a 50% duty cycle (set at 4 s on/o time). Subjects were comfortably seated with 908 of hip and knee¯exion, and the feet were free from touching thē oor. The graded FES protocol began at 0 mAmps and increased by intervals of 16 mAmps with a stimulation on-time of one minute followed by 3 min of o-time (rest), the minimum work : rest ratio to allow for recovery.
The subject's HR and BP were measured. BP was recorded manually by auscultation for all subjects by the research physician, and HR was measured with a PE sport tester (Polar Pacer HR Monitor, Model 45930, Polar Electro, Finland). BP and HR were measured at baseline, and thereafter at each intensity level during stimulation on-time.
In addition to recording HR and BP, blood for measurement of serum catecholamines (epinephrine and norepinephrine) was drawn by the physician through a 24 gauge indwelling heparin-lock intravenous catheter placed into one of the subject's hands. A 10 ml blood sample was taken for catecholamine levels on three occasions during the stimulation protocol: baseline ± after sitting quietly for 30 min (0 mAmps), during stimulation on-time at 50% stimulation intensity (80 mAmps), and during stimulation ontime at 100% stimulation intensity (160 mAmps). The sample was drawn during the work phase of the work : rest cycle. Each blood sample was aliquoted for analysis. The tubes of blood were centrifuged to separate the serum, and the sample for haematocrit was taken immediately in an heparinized micro pipette and stored at 7208C. The sample was treated for catecholamine assay using High-Pressure Liquid Chromatography Separation with Electrochemical Detection. 15 At the end of the stimulation protocol, the subject rested for 15 min and a recording of FESinduced maximal isometric knee extension force at maximal stimulation was made by the same experienced tester using a hand held dynamometer (Nicholas MMT, Lafayette, IN), as per the protocol of Bohannon.
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On the subject's second visit, the above protocol was repeated under the second cream condition. The testing sessions were conducted at the same time each day.
Statistical analysis
A two factor (cream type6stimulus intensity) analysis of variance, with repeated measures on the second 
Results
As stimulation intensity levels increased from 0 to 160 mAmps for all SCI subjects, statistically signi®cant decreases in HR and increases in systolic and diastolic BP, typical of the previously reported FES-induced AD response, were seen ( Figures 1, 2 and 3) . Similarly, there was a trend toward increases in catecholamines (epinephrine and norepinephrine) as stimulus intensity increased, although statistical signi®cance was not achieved (Table 3) . However, no dierence in the HR, BP or catecholamine responses was seen between the two cream conditions. Likewise, the two cream conditions did not signi®cantly aect the FES-induced knee extension force output between anaesthetic cream (21.8 kg+12.4), and placebo cream (21.2 kg+11.8).
Discussion
The purpose of this investigation was to evaluate the eect of topical local anaesthetic cream on FESinduced cardiovascular, hormonal and strength responses. We found that FES applied to the quadriceps muscle in quadriplegics results in a signi®cant increase in BP and decrease in HR, as previously described by Ashley et al. 5 We also detected a trend toward increases in both epinephrine and norepinephrine levels. This again con®rms that FES can induce an AD-like response in individuals with high SCI. It is important to monitor for extreme BP changes associated with FES-induced AD. However, it does not appear that premedicating the site of FES application with topical local anaesthetic is a successful strategy to reduce the AD response in subjects such as participated in our study.
The SCI subjects in this study were recruited on the basis of availability and lesion level being above T6. None of them demonstrated dangerous hypertensive Figure 1 Heart rate response during FES responses to FES, in contrast to some of the subjects studied by Ashley et al, 5 who responded with BP as high as 220/100 mmHg and decreases in HR as much as 40%. The seven SCI subjects who participated in this study could be classi®ed as`mild' AD responders to FES. This study did not determine whether local anaesthetic cream would be helpful for individuals with SCI who demonstrate severe AD reactions to FES, or who have trouble tolerating FES because of partial sensory sparing. Another explanation for the limited BP elevations, bradycardia and catecholamine response seen in the subjects of this study was that they received less total nociceptive stimulus. We measured the response to FES applied to a single leg whereas prior studies described greater FES-induced AD responses as a result of bilateral leg stimulation. 5 The power of this study is limited by the reduced eect of the FES protocol used and the small number of subjects.
The lack of ecacy of the topical anaesthetic cream in suppressing the AD response to FES may be because the nociceptive trigger for FES-induced AD largely comes from the pain of the muscle and not skin stimulation. Topical anaesthetic has been reported to reduce pain up to a depth of 3 mm by reducing free nerve ending sensitivity. This was supported by ®ndings of a pilot project conducted by Matthews et al, 17 in which FES was administered to neurologically normal subjects under topical anaesthetic and placebo conditions, using a similar protocol as described in this study. At lower stimulation intensities, the topical anaesthetic was eective in reducing the subjects' perceived pain, HR and BP response, but the topical anaesthetic lost its ecacy at the higher levels of FES intensity. Thus, FES-induced AD changes in SCI subjects are probably related to more complex mechanisms than skin nociception. High intensity FES results in a tetanic muscle contraction which, in addition to skin nociception, results in contractile unit pain on the basis of muscle ischemia, metabolite accumulation and/or musculotendinous strain. Similar ®ndings have been suggested by Delitto et al.
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It is interesting to note that FES-induced elevations in BP were modest and served to raise the SCI subjects' BP from the typical hypotensive level to a normotensive level for someone who is neurologically intact. This raises the interesting possibility of using FES to treat SCI-related hypotension ± a concept that warrants further study.
Conclusion
This study has demonstrated that FES application to the quadriceps muscle in high level SCI subjects results in signi®cant increases in BP, decreases in HR and trends toward elevations in catecholamine levels (ADlike response). However, this AD-like response is unaected by the use of topical anaesthetic cream on the skin at the stimulation site. This suggests that other mechanisms than skin nociception are operative in FES-induced AD.
